Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Milano
Joined April 2012
- Tweets3K
- Following936
- Followers4.5K
- Likes3.8K
Pinned Tweet
At #ESMO26: In a phase 2a trial, treatment of patients with immune checkpoint-inhibitor-naive bladder cancer with the GDF15-neutralizing antibody visugromab + nivolumab produced encouraging response with no new safety signals @AndreaNecchi dlvr.it/TW32cC
GDF15 neutralization may enable boosting CR rare of EVP allowing surgical and adjuvant therapy de-escalation in MIBC deep responders.
GDFather-Neo was a successful 🇩🇪🇮🇹 trial
Clinical research in 🇪🇺 EU is at a critical step urgent changes are needed
Next week an important bladder cancer table at the EU parliament
@EU_Commission @JNJInnovMedEMEA
#Catalym
nature.com/articles/s41591-0…
Andrea Necchi, MD, FASCO retweeted
@myESMO 2026: Top trending GU cancer oncologists on 𝕏.
Explore #ESMO26 insights here: clin.larvol.com/conference/a…
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer #ClinicalOncology | @DrChoueiri | @tompowles1 | @DrYukselUrun | @DrKarineTawagi | @amerseburger | @nataliagandur | @AndreaNecchi | @Dr_Aggen | @ShingoHatakeya1 | @shilpaonc | @PGrivasMDPhD | @TiansterZhang | @HimanshuNagarMD | @Kenrickng1 | @drmutluhizal
Andrea Necchi, MD, FASCO retweeted
@myESMO 2026: Most discussed GU cancer trials on 𝕏 and key results.
Explore #ESMO26 insights here: clin.larvol.com/conference/a…
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer #ClinicalOncology | @DrChoueiri | @tompowles1 | @DrYukselUrun | @DrKarineTawagi | @amerseburger | @nataliagandur | @AndreaNecchi | @Dr_Aggen | @ShingoHatakeya1 | @shilpaonc | @PGrivasMDPhD | @TiansterZhang | @HimanshuNagarMD | @Kenrickng1 | @drmutluhizal
My choice is easy. @PGrivasMDPhD could be described with many qualities, but most importantly for me is a close friend and part of the @SanRaffaeleMI #GURetreat alumni.
asco.org/about-asco/asco-ove…
Cannot think of a better candidate than @montypal for this prestigious position. A close friend, bright mind, brilliant mentor for many. And part of the @SanRaffaeleMI #GURetreat alumni
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
Andrea Necchi, MD, FASCO retweeted
Watch our recent interview with @AndreaNecchi from #ESMO26 to hear final pathological and radiological outcomes, and initial EFS from the GDFather-NEO trial of nivolumab ± visugromab in #MIBC 📈🔬
🎥: ow.ly/TkLB5101sut
#Oncology @myESMO #TrialUpdate #ImmunoOnc #BladderCancer #BCSM
Andrea Necchi, MD, FASCO retweeted
Outcomes of Patients with #MIBC Who Declined Radical Cystectomy in Perioperative Therapy Trials Conducted at San Raffaele Comprehensive Cancer Center. Presented by @CMercinelli @SanRaffaeleMI. #ESMO26 written coverage by @rksayyid @UAUrology > bit.ly/4Bxa9KE #BladderCancer #GUOnc @myESMO
Our own Michela Piacentini presented the external validation cohort findings of AI-assisted MRI imaging for the prediction of response to neoadj therapies in MIBC
- deep features model performed less well in this cohort vs #PURE01 published in @EurUrolOncol
- pre-therapy imaging prediction remains challenging
- post therapy performance of radiomic features was better
Bladder MRI-based tools remains an area of investigation in pts with MIBC
Congrats to the contributors!
@SanRaffaeleMI @MyUniSR @MSKCancerCenter @BrigidaMaiorano @Anto_cigliola @CMercinelli @GiorgioBre Larry Schwartz, Amita Dave et al. @myESMO #ESMO26 @urotoday @OncoAlert
Our own Debora Serafini presented the #SURE02 trial update after @TheLancetOncol publication early this year #ESMO26 @myESMO
- 39% cCR
- 24m median follow-up
- 2y EFS in cCR pts 83.3%; 2y OS 94.4%
- 81.6% started adjuvant pembro, 42.9% completed the adjuvant course
Some severe delayed irTRAE may still occur.
Congratulations to the entire team!
@SanRaffaeleMI @MyUniSR @CMercinelli @BrigidaMaiorano @Anto_cigliola @BasileG_ et al.@urotoday @OncoAlert
Thank you for highlighting our work!
Bladder preservation after neoadjuvant/perioperative therapy in 🇮🇹 MIBC pts who declined RC and underwent reTURBT (n=54)
📌Negative imaging, biopsy & cytology
🔹19% recurred; 13% developed distant recurrence
🔹 ypT0Nx at reTURBT → 24-mo EFS 88%; MFS & OS >95%, comparable with ypT0N0 after RC
🔹 Residual disease at reTURBT → substantially worse vs non-pCR after RC: 24-mo EFS 19% vs 68%; OS 50% vs 83%
🔹 20% required delayed RC or chemoRT
🔹 Baseline cT3–4 disease also associated with poorer outcomes
🔑 Pathologic clearance at reTURBT may identify a highly selected group for bladder preservation; residual disease was associated with markedly inferior outcomes vs RC.
@urotoday #ESMO26
Andrea Necchi, MD, FASCO retweeted
Really enjoyed being part of the @OncoDaily Bladder Cancer Grand Rounds at #ESMO26
So much is changing in bladder cancer but there are still plenty of questions we don’t have answers to
Special thanks to @AndreaNecchi for bringing us together and leading such a great discussion
Bladder Cancer Grand Rounds happening in Madrid! 🇪🇸
Two sessions bringing the latest evidence and worldwide clinical experience together at OncoDaily Grand Rounds during ESMO 2026.
Part 1, chaired by Prof. @AndreaNecchi, featured educational lectures on:
• Radical cystectomy and bladder preservation — Dr. @DrFelixGuerrero
• Systemic therapy advances in localised bladder cancer — Prof. @AndreaNecchi
• Treatment selection and sequencing in advanced urothelial carcinoma — Dr. Sara Coca Membribes (@scocmem)
• Practical management, toxicity and monitoring — Dr. María José Juan Fita
Part 2, chaired by Dr. María José Juan Fita, brought worldwide experience to the discussion through shared clinical cases. The panel explored the use of enfortumab vedotin plus pembrolizumab, perioperative strategies, treatment sequencing and bladder preservation and how access and reimbursement shape everyday decisions.
Joining the discussion were Dr. Sara Coca Membribes (@scocmem) (United Kingdom), Dr. @DrFelixGuerrero (Spain), Dr. Helena Kremer (Brazil), Dr. Kelvin Yan (Hong Kong, China), Dr. @DrUddiGoswami (India), Dr. Samvel Bardakhchyan (Armenia), Dr. Lazar Popovic (@LazarPo31787807) (Serbia), Prof. Chunguang Yang (China), Dr. Javier Molina Cerrillo (@JaviMolinaC) (Spain) and Dr. Kleida Mati (Albania).
The same clinical scenario can lead to very different treatment choices across countries. Sharing these experiences helps us understand the gaps and what we can do better together.
Thank you to all our faculty and participants for such an open and engaging discussion!
This independent educational activity is supported by a grant from @AstellasUS.
#OncoDaily #ESMO2026
Andrea Necchi, MD, FASCO retweeted
ESMO26: Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer. Watch Prof Andrea Necchi discuss his study👉ow.ly/xfc45100On8 @AndreaNecchi @MyUniSR #ESMO26 #BladderCancer #OncologyResearch
Andrea Necchi, MD, FASCO retweeted
Bladder Cancer Grand Rounds happening in Madrid! 🇪🇸
Two sessions bringing the latest evidence and worldwide clinical experience together at OncoDaily Grand Rounds during ESMO 2026.
Part 1, chaired by Prof. @AndreaNecchi, featured educational lectures on:
• Radical cystectomy and bladder preservation — Dr. @DrFelixGuerrero
• Systemic therapy advances in localised bladder cancer — Prof. @AndreaNecchi
• Treatment selection and sequencing in advanced urothelial carcinoma — Dr. Sara Coca Membribes (@scocmem)
• Practical management, toxicity and monitoring — Dr. María José Juan Fita
Part 2, chaired by Dr. María José Juan Fita, brought worldwide experience to the discussion through shared clinical cases. The panel explored the use of enfortumab vedotin plus pembrolizumab, perioperative strategies, treatment sequencing and bladder preservation and how access and reimbursement shape everyday decisions.
Joining the discussion were Dr. Sara Coca Membribes (@scocmem) (United Kingdom), Dr. @DrFelixGuerrero (Spain), Dr. Helena Kremer (Brazil), Dr. Kelvin Yan (Hong Kong, China), Dr. @DrUddiGoswami (India), Dr. Samvel Bardakhchyan (Armenia), Dr. Lazar Popovic (@LazarPo31787807) (Serbia), Prof. Chunguang Yang (China), Dr. Javier Molina Cerrillo (@JaviMolinaC) (Spain) and Dr. Kleida Mati (Albania).
The same clinical scenario can lead to very different treatment choices across countries. Sharing these experiences helps us understand the gaps and what we can do better together.
Thank you to all our faculty and participants for such an open and engaging discussion!
This independent educational activity is supported by a grant from @AstellasUS.
#OncoDaily #ESMO2026
Andrea Necchi, MD, FASCO retweeted
Catch #ESMO26 on Video with our collaborators at VJ Oncology and their Faculty!
👉 Explore the coverage bit.ly/4jpTaTQ
Exclusive expert interviews from Madrid break down this year’s key trials in minutes. Trusted by healthcare professionals worldwide, with 980K+ annual views.
@drsanjaypopat, @AndreaNecchi, @KoheiShitara, @KevinKalinsky @lab_kok
and many more
Andrea Necchi, MD, FASCO retweeted
Happening now!
Dr Andrea Necchi (@AndreaNecchi) presenting at the OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition during ESMO26 annual meeting.
Dr Necchi discusses the current treatment, ongoing clinical trials and research opportunities in MIBC and NMIBC, real world applications and treatment deescalation strategies and interpretation of molecular markers and whether they should serve for clinical decision making during his state of the art lecture.
@myESMO
Andrea Necchi, MD, FASCO retweeted
OncoDaily Grand Rounds at ESMO 2026: Bladder Cancer Edition has started!
With opening remarks from Dr Amalya Sargsyan (@amalsargsyan) and chair Dr Andrea Necchi (@AndreaNecchi), we begin our grand rounds!
📍Come join us at Calle de Ámsterdam, 3, Campo de las Naciones, Madrid, Spain.
@myESMO
Andrea Necchi, MD, FASCO retweeted
‼️Today in Madrid: OncoDaily Grand Rounds at @myESMO 2026: Bladder Cancer Edition
Chaired by Prof. @AndreaNecchi, the event will bring together expert perspectives, interactive discussions, and real-world clinical scenarios to explore treatment decisions, emerging evidence, and the challenges of bladder cancer management across different healthcare settings.
📍 Novotel Madrid Feria and Airport, Madrid
📅 October 25, 2026 | 1:30–6:00 PM
⏳ Hurry up and register! Don’t miss the opportunity to be part of this important scientific discussion.
🔗 Register now: oncodaily.com/grand-rounds-a…
This event is supported by an independent medical education grant from the @AstellasUS and @pfizer via Pfizer–Astellas Alliance.
#OncoDaily #ESMO2026
Andrea Necchi, MD, FASCO retweeted
GDFATHER-NEO Trial Explores Neoadjuvant Visugromab Plus Nivolumab in MIBC - Andrea Necchi
@AndreaNecchi
oncodaily.com/science/andrea…
Andrea Necchi, MD, FASCO retweeted
Promising data presented by @AndreaNecchi at #ESMO26 #GDFather-NEO.
Nivo + Visugromab
• Higher response (pCR and ORR)
• At median F/U 15.7 mo: no recurrence observed after pCR
• No new safety signal
Paper out in @NatureMedicine. Congrats Andrea and co-authors !
@myESMO @OncoAlert
